President John Dramani Mahama has unveiled the Health Investment and National Gateway, known as H Enabler, as a continental initiative designed to simplify regulatory procedures, strengthen clinical validation and facilitate the commercialisation of health innovations and investments across Africa. The initiative was announced during President Mahama's keynote address at the Alamein Africa Forum in Egypt.
The H Enabler initiative was developed in collaboration with the African Medicines Agency, Institut Pasteur and Afrochampions in response to regulatory and financial obstacles that have continued to impede investment and innovation within Africa's health sector. According to President Mahama, the platform would function as a data-driven framework that brings regulatory procedures, clinical assessment and commercialisation together within a coordinated system.
President Mahama said reducing unnecessary regulatory obstacles is essential to establishing a more effective continental environment for pharmaceutical production and attracting the scale of investment required to expand Africa's health manufacturing capacity. He explained that H Enabler would give health innovators and investors a more structured pathway through the various stages required to take products from development to the marketplace.
Africa currently imports more than 70 per cent of its pharmaceutical products and almost 99 per cent of its vaccines, resulting in substantial financial resources flowing outside the continent. President Mahama said this dependence results in a significant drain on African economies and emphasised the need for greater local production to meet the continent's health needs.
The President also disclosed that, through the Accra Reset Presidential Council, Ghana was deploying specialised task forces and reform interlock observatories to monitor capital movements, follow through on policy commitments and identify non-tariff barriers that continue to obstruct the development of regional value chains. He called for stronger participation from private investors, industrial developers, commercial banks and sovereign wealth funds in the expansion of Africa's pharmaceutical and broader health manufacturing sector.
President Mahama urged African regulators to accelerate the operationalisation of the African Medicines Agency, stressing the importance of a harmonised regulatory environment across the continent. He said an effectively coordinated system could allow a medicine that receives approval through a harmonised continental framework to gain access to multiple African markets without manufacturers having to navigate entirely separate approval processes in every country.
The H Enabler initiative places regulatory coordination, investment mobilisation, clinical validation and commercialisation within a broader continental effort to build stronger African health industries and retain more of the economic value generated by the sector within the continent. President Mahama maintained that closer cooperation among African regulatory authorities, coupled with increased investment in domestic pharmaceutical manufacturing, would be central to strengthening Africa's health sovereignty.
Key points
- The H Enabler initiative aims to simplify regulatory procedures and facilitate health innovations and investments across Africa.
- Africa currently imports more than 70 per cent of its pharmaceutical products and almost 99 per cent of its vaccines.
- President Mahama called for stronger participation from private investors, industrial developers, commercial banks and sovereign wealth funds in the expansion of Africa's pharmaceutical and broader health manufacturing sector.
